loading page

A nationwide survey of late effects in survivors of juvenile myelomonocytic leukemia in Japan
  • +7
  • Shuichi Ozono,
  • Kazuo Sakashita,
  • Nao Yoshida,
  • Harumi Kakuda,
  • Kenichiro Watanabe,
  • Miho Maeda,
  • Yasushi Ishida,
  • Atsushi Manabe,
  • Takashi Taga,
  • Hideki Muramatsu
Shuichi Ozono
Kurume Daigaku Igakubu Daigakuin Igaku Kenkyuka Shonikagaku Kyoshitsu

Corresponding Author:ohzono_shyuuichi@kurume-u.ac.jp

Author Profile
Kazuo Sakashita
Japan Children’s Cancer Group (JCCG)
Author Profile
Nao Yoshida
Japan Children’s Cancer Group (JCCG)
Author Profile
Harumi Kakuda
Japan Children’s Cancer Group (JCCG)
Author Profile
Kenichiro Watanabe
Japan Children’s Cancer Group (JCCG)
Author Profile
Miho Maeda
Japan Children’s Cancer Group (JCCG)
Author Profile
Yasushi Ishida
Japan Children’s Cancer Group (JCCG)
Author Profile
Atsushi Manabe
Japan Children’s Cancer Group (JCCG)
Author Profile
Takashi Taga
Japan Children’s Cancer Group (JCCG)
Author Profile
Hideki Muramatsu
Japan Children’s Cancer Group (JCCG)
Author Profile

Abstract

We conducted a cross-sectional study using a questionnaire to explore the late effects in survivors of juvenile myelomonocytic leukemia (JMML). The attending pediatric hematologist oncologists completed the questionnaires. All survivors (N=30) had undergone allogeneic hematopoietic stem cell transplantation. Approximately 83% survivors showed more than one late effect. The identified late effects included endocrine, dental, skin, ophthalmologic, musculoskeletal, pulmonary, neurocognitive, and cardiovascular dysfunction. The prevalence of short stature and cardiovascular and kidney dysfunction was significantly elevated among survivors aged ≥18 years. Therefore, a multidisciplinary follow-up system for survivors of JMML is crucial.
15 Aug 2022Submission Checks Completed
15 Aug 2022Assigned to Editor
15 Aug 2022Submitted to Pediatric Blood & Cancer
22 Aug 2022Reviewer(s) Assigned
17 Sep 2022Review(s) Completed, Editorial Evaluation Pending
19 Sep 2022Editorial Decision: Revise Minor
22 Oct 2022Submission Checks Completed
22 Oct 2022Assigned to Editor
22 Oct 20221st Revision Received
22 Oct 2022Review(s) Completed, Editorial Evaluation Pending
22 Oct 2022Reviewer(s) Assigned
09 Nov 2022Editorial Decision: Accept
Feb 2023Published in Pediatric Blood & Cancer volume 70 issue 2. 10.1002/pbc.30126